Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Détail de l'auteur
Auteur Anya MAZUR-MOSIEWICZ |
Documents disponibles écrits par cet auteur (1)
Faire une suggestion Affiner la recherche
The impact of COVID-19 on autism research: A cross-sectional analysis of discontinued or suspended clinical trials / Monika NEALE in Autism Research, 15-8 (August 2022)
[article]
Titre : The impact of COVID-19 on autism research: A cross-sectional analysis of discontinued or suspended clinical trials Type de document : Texte imprimé et/ou numérique Auteurs : Monika NEALE, Auteur ; Elizabeth LANDERS, Auteur ; Nicholas B. SAJJADI, Auteur ; Anya MAZUR-MOSIEWICZ, Auteur ; Micah HARTWELL, Auteur Article en page(s) : p.1560-1564 Langues : Anglais (eng) Mots-clés : Autism Spectrum Disorder/epidemiology Autistic Disorder/epidemiology covid-19 Cross-Sectional Studies Humans Pandemics Covid-19 autism clinical trials discontinuation pandemic Index. décimale : PER Périodiques Résumé : Due to uncertainties associated with the COVID-19 public health crisis, several clinical trials had to be withdrawn or postponed. Our investigation aimed to assess the rate of discontinuation of clinical trials focusing on Autism Spectrum Disorder. Of the 197 registered trials included in our systematic review, 15 (7.6%) were discontinued, with nearly half of these explicitly citing COVID-19 as their reason for discontinuation. Pharmacological trials were six times more likely to be discontinued during the pandemic than non-pharmacological studies. The difference between the likelihood of discontinuation was statistically significant (OR: 6.13; 95% CI: 1.22-30.71). There was no evidence of association between funding source and reasons for discontinuation. Limitations, along with implications for future trials are discussed. LAY SUMMARY: We investigated the impact of the COVID-19 pandemic on the discontinuation rate of autism clinical trials. We found that drug trials were six times more likely to be discontinued during the pandemic compared to behavioral, diagnostic, and nutritional trials. The overall discontinuation rate was notably lower in autism clinical trials than in other areas of medical research. We recommend an examination of the methodology of the continued autism trials to assess their applicability in other fields. En ligne : http://dx.doi.org/10.1002/aur.2764 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=483
in Autism Research > 15-8 (August 2022) . - p.1560-1564[article] The impact of COVID-19 on autism research: A cross-sectional analysis of discontinued or suspended clinical trials [Texte imprimé et/ou numérique] / Monika NEALE, Auteur ; Elizabeth LANDERS, Auteur ; Nicholas B. SAJJADI, Auteur ; Anya MAZUR-MOSIEWICZ, Auteur ; Micah HARTWELL, Auteur . - p.1560-1564.
Langues : Anglais (eng)
in Autism Research > 15-8 (August 2022) . - p.1560-1564
Mots-clés : Autism Spectrum Disorder/epidemiology Autistic Disorder/epidemiology covid-19 Cross-Sectional Studies Humans Pandemics Covid-19 autism clinical trials discontinuation pandemic Index. décimale : PER Périodiques Résumé : Due to uncertainties associated with the COVID-19 public health crisis, several clinical trials had to be withdrawn or postponed. Our investigation aimed to assess the rate of discontinuation of clinical trials focusing on Autism Spectrum Disorder. Of the 197 registered trials included in our systematic review, 15 (7.6%) were discontinued, with nearly half of these explicitly citing COVID-19 as their reason for discontinuation. Pharmacological trials were six times more likely to be discontinued during the pandemic than non-pharmacological studies. The difference between the likelihood of discontinuation was statistically significant (OR: 6.13; 95% CI: 1.22-30.71). There was no evidence of association between funding source and reasons for discontinuation. Limitations, along with implications for future trials are discussed. LAY SUMMARY: We investigated the impact of the COVID-19 pandemic on the discontinuation rate of autism clinical trials. We found that drug trials were six times more likely to be discontinued during the pandemic compared to behavioral, diagnostic, and nutritional trials. The overall discontinuation rate was notably lower in autism clinical trials than in other areas of medical research. We recommend an examination of the methodology of the continued autism trials to assess their applicability in other fields. En ligne : http://dx.doi.org/10.1002/aur.2764 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=483